Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Novel Viral Vaccine and Molecular Immunology
share announcement

Novel Viral Vaccine and Molecular Immunology

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cellular/Molecular Immunology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 485

Special Issue Editor

Dr. Chang Li

E-Mail
Guest Editor
1. Research Unit of Key Technologies for Prevention and Control of Virus Zoonoses, Chinese Academy of Medical Sciences, Changchun 130122, China
2. Changchun Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences, Changchun 130122, China
Interests: viral infection and immunity; viral–host interaction; viral diagnosis; viral vaccine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Viral infections pose a serious threat to public health, and vaccines are the most effective and affordable measures to control them. New technologies and vaccines are being developed, including DNA vaccines, mRNA vaccines, multi-epitope vaccines, synthetic peptide vaccines, vaccines targeting dendritic cells, and mucosal vaccines. However, safety, effectiveness, controllability, and cost remain concerns, and the continuous mutation of viruses is an ongoing challenge. We welcome your latest research on develo** novel technologies and vaccines against viral infections, including clinical trials, molecular immunology, and new strategies. Research areas include designing and evaluating vaccines, develo** universal vaccines, identifying immunogen targets of viruses, develo** new tools for predicting antigens and their application and studying the immune mechanism of vaccines, especially mucosal vaccines.

Dr. Chang Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • viral infectious diseases
  • novel vaccines
  • immune mechanism

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1102 KiB  
Article
The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice
by Jie Yang, Huifen Fan, Anna Yang, Wenhui Wang, **n Wan, Fengjie Lin, Dongsheng Yang, Jie Wu, Kaiwen Wang, Wei Li, Qian Cai, Lei You, Deqin Pang, Jia Lu, Changfu Guo, **rong Shi, Yan Sun, **nguo Li, Kai Duan, Shuo Shen, Shengli Meng, **g Guo and Zejun Wangadd Show full author list remove Hide full author list
Vaccines 2024, 12(7), 742; https://doi.org/10.3390/vaccines12070742 - 3 Jul 2024
Viewed by 264
Abstract
The emergence of SARS-CoV-2 variants of concern (VOCs) with increased transmissibility and partial resistance to neutralization by antibodies has been observed globally. There is an urgent need for an effective vaccine to combat these variants. Our study demonstrated that the B.1.351 variant inactivated [...] Read more.
The emergence of SARS-CoV-2 variants of concern (VOCs) with increased transmissibility and partial resistance to neutralization by antibodies has been observed globally. There is an urgent need for an effective vaccine to combat these variants. Our study demonstrated that the B.1.351 variant inactivated vaccine candidate (B.1.351V) generated strong binding and neutralizing antibody responses in BALB/c mice against the B.1.351 virus and other SARS-CoV-2 variants after two doses within 28 days. Immunized K18-hACE2 mice also exhibited elevated levels of live virus-neutralizing antibodies against various SARS-CoV-2 viruses. Following infection with these viruses, K18-hACE2 mice displayed a stable body weight, a high survival rate, minimal virus copies in lung tissue, and no lung damage compared to the control group. These findings indicate that B.1.351V offered protection against infection with multiple SARS-CoV-2 variants in mice, providing insights for the development of a vaccine targeting SARS-CoV-2 VOCs for human use. Full article
(This article belongs to the Special Issue Novel Viral Vaccine and Molecular Immunology)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop